首页 > 最新文献

Canadian Journal of Gastroenterology最新文献

英文 中文
A meta-analysis of adjuvant therapy after potentially curative treatment for hepatocellular carcinoma. 肝细胞癌潜在治愈治疗后辅助治疗的荟萃分析。
IF 2.7 4区 医学 Q2 Medicine Pub Date : 2013-06-01 DOI: 10.1155/2013/417894
Jun Wang, Xiao Dong He, Nan Yao, Wen Jia Liang, You Cheng Zhang

Background: The high recurrence rate of hepatocellular carcinoma (HCC) after potentially curative treatment determines the long-term prognosis.

Objective: To evaluate the efficacy and safety of adjuvant therapies in patients with HCC who have undergone hepatic resection, transplantation or locoregional ablation therapy.

Methods: Several databases were searched to identify randomized controlled trials (RCTs) fulfilling the predefined selection criteria. Meta-analyses were performed to estimate the effects of adjuvant therapies of any modality on recurrence-free survival (RFS) and overall survival (OS).

Results: Eight adjuvant modalities were identified from 27 eligible RCTs conducted predominantly in Asian populations comparing adjuvant with no adjuvant therapy. Adjuvant chemotherapy, internal radiation and heparanase inhibitor PI-88 therapy failed to improve RFS or OS, while interferon (IFN) therapy yielded significant survival results. The findings of adjuvant vitamin analogue therapy required further examination. Adjuvant adoptive immunotherapy conferred significant benefit for RFS but not for OS. Although cancer vaccine therapy and radioimmunotherapy may improve survival after radical surgery, the results were from single, small-scale trials. Severe side effects were observed in the studies of adjuvant chemotherapy and of IFN therapy.

Conclusions: Adjuvant IFN therapy can improve both RFS and OS; however, the benefits of using this agent should be weighed against its side effects. Combination of systemic and transhepatic arterial chemotherapy is not recommended for HCC after potentially curative treatment. Other adjuvant therapies produce limited success for survival. Additional RCTs with proper design are required to establish the role of adjuvant therapies for HCC.

背景:肝细胞癌(HCC)在潜在治愈治疗后的高复发率决定了其长期预后。目的:评价肝癌患者行肝切除、肝移植或局部消融术后辅助治疗的有效性和安全性。方法:检索多个数据库,以确定符合预定义选择标准的随机对照试验(rct)。进行荟萃分析以评估任何辅助治疗方式对无复发生存期(RFS)和总生存期(OS)的影响。结果:从27项主要在亚洲人群中进行的符合条件的随机对照试验中确定了8种辅助治疗方式,比较了辅助治疗和无辅助治疗。辅助化疗、内放疗和肝素酶抑制剂PI-88治疗未能改善RFS或OS,而干扰素(IFN)治疗取得了显著的生存结果。辅助维生素类似物治疗的结果需要进一步检查。辅助过继免疫治疗对RFS有显著的益处,但对OS没有。虽然癌症疫苗治疗和放射免疫治疗可能提高根治性手术后的生存率,但结果来自单一的小规模试验。在辅助化疗和干扰素治疗的研究中观察到严重的副作用。结论:IFN辅助治疗可改善RFS和OS;然而,使用这种药物的好处应该与其副作用进行权衡。在有治愈潜力的肝细胞癌治疗后,不推荐全身和经肝动脉联合化疗。其他辅助治疗对生存率的影响有限。需要更多设计合理的随机对照试验来确定HCC辅助治疗的作用。
{"title":"A meta-analysis of adjuvant therapy after potentially curative treatment for hepatocellular carcinoma.","authors":"Jun Wang,&nbsp;Xiao Dong He,&nbsp;Nan Yao,&nbsp;Wen Jia Liang,&nbsp;You Cheng Zhang","doi":"10.1155/2013/417894","DOIUrl":"https://doi.org/10.1155/2013/417894","url":null,"abstract":"<p><strong>Background: </strong>The high recurrence rate of hepatocellular carcinoma (HCC) after potentially curative treatment determines the long-term prognosis.</p><p><strong>Objective: </strong>To evaluate the efficacy and safety of adjuvant therapies in patients with HCC who have undergone hepatic resection, transplantation or locoregional ablation therapy.</p><p><strong>Methods: </strong>Several databases were searched to identify randomized controlled trials (RCTs) fulfilling the predefined selection criteria. Meta-analyses were performed to estimate the effects of adjuvant therapies of any modality on recurrence-free survival (RFS) and overall survival (OS).</p><p><strong>Results: </strong>Eight adjuvant modalities were identified from 27 eligible RCTs conducted predominantly in Asian populations comparing adjuvant with no adjuvant therapy. Adjuvant chemotherapy, internal radiation and heparanase inhibitor PI-88 therapy failed to improve RFS or OS, while interferon (IFN) therapy yielded significant survival results. The findings of adjuvant vitamin analogue therapy required further examination. Adjuvant adoptive immunotherapy conferred significant benefit for RFS but not for OS. Although cancer vaccine therapy and radioimmunotherapy may improve survival after radical surgery, the results were from single, small-scale trials. Severe side effects were observed in the studies of adjuvant chemotherapy and of IFN therapy.</p><p><strong>Conclusions: </strong>Adjuvant IFN therapy can improve both RFS and OS; however, the benefits of using this agent should be weighed against its side effects. Combination of systemic and transhepatic arterial chemotherapy is not recommended for HCC after potentially curative treatment. Other adjuvant therapies produce limited success for survival. Additional RCTs with proper design are required to establish the role of adjuvant therapies for HCC.</p>","PeriodicalId":55285,"journal":{"name":"Canadian Journal of Gastroenterology","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2013-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2013/417894","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31611012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 55
Summary of guidelines for infection prevention and control for flexible gastrointestinal endoscopy. 柔性消化道内窥镜检查感染预防与控制指南摘要。
IF 2.7 4区 医学 Q2 Medicine Pub Date : 2013-06-01 DOI: 10.1155/2013/639518
Lawrence Hookey, David Armstrong, Rob Enns, Anne Matlow, Harminder Singh, Jonathan Love

Background: High-quality processes to ensure infection prevention and control in the delivery of safe endoscopy services are essential. In 2010, the Public Health Agency of Canada and the Canadian Association of Gastroenterology (CAG) developed a Canadian guideline for the reprocessing of flexible gastrointestinal endoscopy equipment.

Methods: The CAG Endoscopy Committee carefully reviewed the 2010 guidelines and prepared an executive summary.

Results: Key elements relevant to infection prevention and control for flexible gastrointestinal endoscopy were highlighted for each of the recommendations included in the 2010 document. The 2010 guidelines consist of seven sections, including administrative recommendations, as well as recommendations for endoscopy and endoscopy decontamination equipment, reprocessing endoscopes and accessories, endoscopy unit design, quality management, outbreak investigation and management, and classic and variant Creutzfeldt-Jakob Disease.

Discussion: The recommendations for infection prevention and control for flexible gastrointestinal endoscopy are intended for all individuals with responsibility for endoscopes in all settings where endoscopy is performed.

背景:在提供安全的内窥镜检查服务时,确保感染预防和控制的高质量流程至关重要。2010 年,加拿大公共卫生署和加拿大胃肠病学协会 (CAG) 制定了加拿大柔性胃肠道内窥镜设备再处理指南:方法:加拿大胃肠病协会内镜委员会仔细审查了 2010 年指南,并编写了一份执行摘要:结果:2010 年文件中的每项建议都强调了与柔性消化道内窥镜感染预防和控制相关的关键要素。2010 年指南由七个部分组成,包括管理建议、内镜和内镜净化设备建议、内镜和附件再处理建议、内镜室设计建议、质量管理建议、疫情调查和管理建议以及典型和变异克雅氏病建议:讨论:有关柔性消化道内窥镜感染预防和控制的建议适用于在进行内窥镜检查的所有环境中负责内窥镜的所有人员。
{"title":"Summary of guidelines for infection prevention and control for flexible gastrointestinal endoscopy.","authors":"Lawrence Hookey, David Armstrong, Rob Enns, Anne Matlow, Harminder Singh, Jonathan Love","doi":"10.1155/2013/639518","DOIUrl":"10.1155/2013/639518","url":null,"abstract":"<p><strong>Background: </strong>High-quality processes to ensure infection prevention and control in the delivery of safe endoscopy services are essential. In 2010, the Public Health Agency of Canada and the Canadian Association of Gastroenterology (CAG) developed a Canadian guideline for the reprocessing of flexible gastrointestinal endoscopy equipment.</p><p><strong>Methods: </strong>The CAG Endoscopy Committee carefully reviewed the 2010 guidelines and prepared an executive summary.</p><p><strong>Results: </strong>Key elements relevant to infection prevention and control for flexible gastrointestinal endoscopy were highlighted for each of the recommendations included in the 2010 document. The 2010 guidelines consist of seven sections, including administrative recommendations, as well as recommendations for endoscopy and endoscopy decontamination equipment, reprocessing endoscopes and accessories, endoscopy unit design, quality management, outbreak investigation and management, and classic and variant Creutzfeldt-Jakob Disease.</p><p><strong>Discussion: </strong>The recommendations for infection prevention and control for flexible gastrointestinal endoscopy are intended for all individuals with responsibility for endoscopes in all settings where endoscopy is performed.</p>","PeriodicalId":55285,"journal":{"name":"Canadian Journal of Gastroenterology","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2013-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3684370/pdf/cjg27347.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31611010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The epidemiology of hepatitis C in a Canadian Indigenous population. 加拿大土著居民丙型肝炎流行病学研究。
IF 2.7 4区 医学 Q2 Medicine Pub Date : 2013-06-01 DOI: 10.1155/2013/380963
Julia Uhanova, Robert B Tate, Douglas J Tataryn, Gerald Y Minuk

Background: An estimated 1% to 1.9% of North Americans are infected with the hepatitis C virus (HCV). Although Indigenous peoples are considered to bear the highest burden, there are only limited data regarding the demographic features and epidemiology of hepatitis C in this population.

Objectives: To document the demographic characteristics, rates of newly diagnosed hepatitis C cases and prevalence of HCV infection in a Canadian First Nations population, and to compare the findings with an infected non-First Nations population.

Methods: A research database spanning 1991 to 2002 was developed, linking records from multiple clinical and administrative sources. Over a 12-year period, 671 First Nations and 4347 non-First Nations HCV-positive Canadians were identified in the province of Manitoba. Demographics, residence and time trends were compared between infected First Nations and non-First Nations persons.

Results: HCV-infected First Nations individuals were younger (mean [± SD] age 33.0±0.4 years versus 39.7±0.2 years; P<0.0001), more often female (60% versus 40%; P<0.0001) and more often resided in urban centres (73% versus 27%; P<0.001). The rate of newly diagnosed HCV cases was 2.5-fold (91.1 per 100,000 versus 36.6 per 100,000; P<0.000) and prevalence 2.4-fold (801.7 per 100,000 versus 334.8 per 100,000; P<0.000) higher among the First Nations relative to non-First Nations populations.

Conclusions: The results of the present large population-based study indicate that the First Nations population with hepatitis C is characteristically different from infected non-First Nations persons. The results also describe higher rates of newly diagnosed cases and prevalence of HCV infection in the First Nations population. These findings should serve as an important baseline for future primary prevention and therapeutic intervention strategies in this high-risk population.

背景:估计有1%至1.9%的北美人感染丙型肝炎病毒(HCV)。尽管土著人民被认为负担最重,但关于这一人群中丙型肝炎的人口特征和流行病学的数据有限。目的:记录加拿大第一民族人群的人口统计学特征、新诊断的丙型肝炎病例率和丙型肝炎感染率,并将这些发现与感染的非第一民族人群进行比较。方法:建立了一个1991年至2002年的研究数据库,将多个临床和行政来源的记录联系起来。在12年的时间里,马尼托巴省发现了671名第一民族和4347名非第一民族hcv阳性的加拿大人。比较了第一民族和非第一民族感染者的人口统计、居住和时间趋势。结果:感染hcv的原住民个体更年轻(平均[±SD]年龄33.0±0.4岁vs 39.7±0.2岁;结论:目前基于人群的大型研究结果表明,第一民族丙型肝炎患者与非第一民族感染者具有不同的特征。研究结果还描述了第一民族人口中新诊断病例和丙型肝炎病毒感染率较高的情况。这些发现应该作为未来高危人群一级预防和治疗干预策略的重要基线。
{"title":"The epidemiology of hepatitis C in a Canadian Indigenous population.","authors":"Julia Uhanova,&nbsp;Robert B Tate,&nbsp;Douglas J Tataryn,&nbsp;Gerald Y Minuk","doi":"10.1155/2013/380963","DOIUrl":"https://doi.org/10.1155/2013/380963","url":null,"abstract":"<p><strong>Background: </strong>An estimated 1% to 1.9% of North Americans are infected with the hepatitis C virus (HCV). Although Indigenous peoples are considered to bear the highest burden, there are only limited data regarding the demographic features and epidemiology of hepatitis C in this population.</p><p><strong>Objectives: </strong>To document the demographic characteristics, rates of newly diagnosed hepatitis C cases and prevalence of HCV infection in a Canadian First Nations population, and to compare the findings with an infected non-First Nations population.</p><p><strong>Methods: </strong>A research database spanning 1991 to 2002 was developed, linking records from multiple clinical and administrative sources. Over a 12-year period, 671 First Nations and 4347 non-First Nations HCV-positive Canadians were identified in the province of Manitoba. Demographics, residence and time trends were compared between infected First Nations and non-First Nations persons.</p><p><strong>Results: </strong>HCV-infected First Nations individuals were younger (mean [± SD] age 33.0±0.4 years versus 39.7±0.2 years; P<0.0001), more often female (60% versus 40%; P<0.0001) and more often resided in urban centres (73% versus 27%; P<0.001). The rate of newly diagnosed HCV cases was 2.5-fold (91.1 per 100,000 versus 36.6 per 100,000; P<0.000) and prevalence 2.4-fold (801.7 per 100,000 versus 334.8 per 100,000; P<0.000) higher among the First Nations relative to non-First Nations populations.</p><p><strong>Conclusions: </strong>The results of the present large population-based study indicate that the First Nations population with hepatitis C is characteristically different from infected non-First Nations persons. The results also describe higher rates of newly diagnosed cases and prevalence of HCV infection in the First Nations population. These findings should serve as an important baseline for future primary prevention and therapeutic intervention strategies in this high-risk population.</p>","PeriodicalId":55285,"journal":{"name":"Canadian Journal of Gastroenterology","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2013-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2013/380963","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31611008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 32
Hepatitis C virus infection in Canada's First Nations people: a growing problem. 加拿大原住民的丙型肝炎病毒感染:一个日益严重的问题。
IF 2.7 4区 医学 Q2 Medicine Pub Date : 2013-06-01 DOI: 10.1155/2013/641585
Matthew D Sadler, Samuel S Lee
As of 2007, it was estimated that 240,000 Canadians were chronically infected with hepatitis C virus (HCV), with higher rates in certain at-risk populations (1). It is possible that this figure underestimates the prevalence of HCV infection, and other estimates are significantly higher (2,3). Unfortunately, firm data regarding national prevalence are lacking. What is clear is that the greatest risk for acute HCV infection is intravenous drug use, which accounts for nearly two-thirds of new cases in Canada (1). Population-based studies on the incidence and prevalence of HCV infection in Canada are sparse. Despite this, there have been several studies that show higher rates of HCV infection in Aboriginal people; however, these studies have only examined high-risk groups within the Aboriginal community such as incarcerated persons and intravenous drug users. In the current issue of the Canadian Journal of Gastroenterology, Uhanova et al (4) (pages 336–340) describe the incidence and prevalence of HCV infection in a Canadian First Nations population. This study is important in that it is the first population-based study to examine HCV infection in this group. The investigators used the Manitoba Health Plan Registry to identify 671 First Nations individuals in Manitoba who tested positive for HCV between 1991 and 2002. The majority of HCV-infected Aboriginal individuals lived in an urban setting despite the fact that most First Nations people were rural habitants. Uhanova et al confirmed previous studies that showed a higher prevalence of HCV in First Nations people compared with non-Aboriginals. Surprisingly, the authors show that more female than male aboriginals acquired HCV in that time period, a trend that is opposite to what has been reported in the non-Aboriginal population (4). It is also concerning that despite a decreasing incidence of HCV infection in the general Canadian population, this study shows that the rate of new HCV infections in the First Nations population is increasing (4). There are, however, a few important limitations to this study. First, the authors did not describe the rate of spontaneous clearance of HCV, which has been shown to occur more frequently in Aboriginals, especially First Nations women (5). The prevalence of HCV in the First Nations population may, therefore, be overestimated due to an inability to ascertain who cleared HCV between 1991 and 1995. Along these same lines, it would be helpful to know the rate of HCV-HIV coinfection in this population because individuals coinfected with HIV are less likely to spontaneously clear HCV (5). Furthermore, the authors did not categorize HCV infection according to genotype. Because HCV genotype has major implications on hepatitis C treatment and rates of clearance with treatment, it would be useful to know whether there are differences in the HCV genotypes acquired by Aboriginals compared with non-Aboriginals. Finally, the definition of First Nations in this stud
{"title":"Hepatitis C virus infection in Canada's First Nations people: a growing problem.","authors":"Matthew D Sadler,&nbsp;Samuel S Lee","doi":"10.1155/2013/641585","DOIUrl":"https://doi.org/10.1155/2013/641585","url":null,"abstract":"As of 2007, it was estimated that 240,000 Canadians were chronically infected with hepatitis C virus (HCV), with higher rates in certain at-risk populations (1). It is possible that this figure underestimates the prevalence of HCV infection, and other estimates are significantly higher (2,3). Unfortunately, firm data regarding national prevalence are lacking. What is clear is that the greatest risk for acute HCV infection is intravenous drug use, which accounts for nearly two-thirds of new cases in Canada (1). Population-based studies on the incidence and prevalence of HCV infection in Canada are sparse. Despite this, there have been several studies that show higher rates of HCV infection in Aboriginal people; however, these studies have only examined high-risk groups within the Aboriginal community such as incarcerated persons and intravenous drug users. \u0000 \u0000In the current issue of the Canadian Journal of Gastroenterology, Uhanova et al (4) (pages 336–340) describe the incidence and prevalence of HCV infection in a Canadian First Nations population. This study is important in that it is the first population-based study to examine HCV infection in this group. The investigators used the Manitoba Health Plan Registry to identify 671 First Nations individuals in Manitoba who tested positive for HCV between 1991 and 2002. The majority of HCV-infected Aboriginal individuals lived in an urban setting despite the fact that most First Nations people were rural habitants. Uhanova et al confirmed previous studies that showed a higher prevalence of HCV in First Nations people compared with non-Aboriginals. Surprisingly, the authors show that more female than male aboriginals acquired HCV in that time period, a trend that is opposite to what has been reported in the non-Aboriginal population (4). It is also concerning that despite a decreasing incidence of HCV infection in the general Canadian population, this study shows that the rate of new HCV infections in the First Nations population is increasing (4). \u0000 \u0000There are, however, a few important limitations to this study. First, the authors did not describe the rate of spontaneous clearance of HCV, which has been shown to occur more frequently in Aboriginals, especially First Nations women (5). The prevalence of HCV in the First Nations population may, therefore, be overestimated due to an inability to ascertain who cleared HCV between 1991 and 1995. Along these same lines, it would be helpful to know the rate of HCV-HIV coinfection in this population because individuals coinfected with HIV are less likely to spontaneously clear HCV (5). \u0000 \u0000Furthermore, the authors did not categorize HCV infection according to genotype. Because HCV genotype has major implications on hepatitis C treatment and rates of clearance with treatment, it would be useful to know whether there are differences in the HCV genotypes acquired by Aboriginals compared with non-Aboriginals. Finally, the definition of First Nations in this stud","PeriodicalId":55285,"journal":{"name":"Canadian Journal of Gastroenterology","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2013-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2013/641585","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31611007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Postoperative delirium in the intensive care unit predicts worse outcomes in liver transplant recipients. 重症监护病房的术后谵妄预示着肝移植受者更糟糕的预后。
IF 2.7 4区 医学 Q2 Medicine Pub Date : 2013-04-01 DOI: 10.1155/2013/289185
Thomas Lescot, Constantine J Karvellas, Prosanto Chaudhury, Jean Tchervenkov, Steven Paraskevas, Jeffrey Barkun, Peter Metrakos, Peter Goldberg, Sheldon Magder

Background: Delirium is common in intensive care unit patients and is associated with worse outcome.

Objective: To identify early risk factors for delirium in patients admitted to the intensive care unit following orthotopic liver transplantation (OLT).

Methods: An observational study of patients admitted to the intensive care unit from January 2000 to May 2010 for elective or semi-elective OLT was conducted. The primary end point was delirium in the intensive care unit. Pre- and post-transplantation and intraoperative factors potentially associated with this outcome were examined.

Results: Of the 281 patients included in the study, 28 (10.03%) developed delirium in the intensive care unit at a median of two days (interquartile range one to seven days) after OLT. According to multivariate analysis, independent risk factors for delirium were intraoperative transfusion of packed red blood cells (OR 1.15 [95% CI 1.01 to 1.18]), renal replacement therapy during the pretransplantation period (OR 13.12 [95% CI 2.82 to 72.12]) and Acute Physiologic and Health Evaluation (APACHE) II score (OR per unit increase 1.10 [95% CI 1.03 to 1.29]). Using Cox proportional hazards models adjusted for baseline covariates, delirium was associated with an almost twofold risk of remaining in hospital, a fourfold increased risk of dying in hospital and an almost threefold increased rate of death by one year.

Conclusion: Intraoperative transfusion of packed red blood cells, pretransplantation renal replacement therapy and APACHE II score are predictors for the development of delirium in intensive care unit patients post-OLT and are associated with increased hospital lengths of stay and mortality.

背景:谵妄在重症监护病房患者中很常见,并与较差的预后相关。目的:探讨重症监护病房原位肝移植(OLT)术后谵妄的早期危险因素。方法:对2000年1月至2010年5月icu收治的选择性或半选择性OLT患者进行观察性研究。主要终点是重症监护病房的谵妄。研究了移植前后和术中可能与该结果相关的因素。结果:在纳入研究的281例患者中,有28例(10.03%)在OLT后中位数为2天(四分位数范围为1至7天)在重症监护病房发生谵妄。根据多因素分析,谵妄的独立危险因素是术中输注填充红细胞(OR 1.15 [95% CI 1.01 ~ 1.18])、移植前肾脏替代治疗(OR 13.12 [95% CI 2.82 ~ 72.12])和急性生理健康评估(APACHE) II评分(OR每单位增加1.10 [95% CI 1.03 ~ 1.29])。使用调整基线协变量的Cox比例风险模型,谵妄与住院的风险增加近两倍,在医院死亡的风险增加四倍,一年的死亡率增加近三倍相关。结论:术中输血填充红细胞、移植前肾脏替代治疗和APACHE II评分是olt后重症监护病房患者谵妄发生的预测因素,并与住院时间和死亡率增加相关。
{"title":"Postoperative delirium in the intensive care unit predicts worse outcomes in liver transplant recipients.","authors":"Thomas Lescot,&nbsp;Constantine J Karvellas,&nbsp;Prosanto Chaudhury,&nbsp;Jean Tchervenkov,&nbsp;Steven Paraskevas,&nbsp;Jeffrey Barkun,&nbsp;Peter Metrakos,&nbsp;Peter Goldberg,&nbsp;Sheldon Magder","doi":"10.1155/2013/289185","DOIUrl":"https://doi.org/10.1155/2013/289185","url":null,"abstract":"<p><strong>Background: </strong>Delirium is common in intensive care unit patients and is associated with worse outcome.</p><p><strong>Objective: </strong>To identify early risk factors for delirium in patients admitted to the intensive care unit following orthotopic liver transplantation (OLT).</p><p><strong>Methods: </strong>An observational study of patients admitted to the intensive care unit from January 2000 to May 2010 for elective or semi-elective OLT was conducted. The primary end point was delirium in the intensive care unit. Pre- and post-transplantation and intraoperative factors potentially associated with this outcome were examined.</p><p><strong>Results: </strong>Of the 281 patients included in the study, 28 (10.03%) developed delirium in the intensive care unit at a median of two days (interquartile range one to seven days) after OLT. According to multivariate analysis, independent risk factors for delirium were intraoperative transfusion of packed red blood cells (OR 1.15 [95% CI 1.01 to 1.18]), renal replacement therapy during the pretransplantation period (OR 13.12 [95% CI 2.82 to 72.12]) and Acute Physiologic and Health Evaluation (APACHE) II score (OR per unit increase 1.10 [95% CI 1.03 to 1.29]). Using Cox proportional hazards models adjusted for baseline covariates, delirium was associated with an almost twofold risk of remaining in hospital, a fourfold increased risk of dying in hospital and an almost threefold increased rate of death by one year.</p><p><strong>Conclusion: </strong>Intraoperative transfusion of packed red blood cells, pretransplantation renal replacement therapy and APACHE II score are predictors for the development of delirium in intensive care unit patients post-OLT and are associated with increased hospital lengths of stay and mortality.</p>","PeriodicalId":55285,"journal":{"name":"Canadian Journal of Gastroenterology","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2013-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2013/289185","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31383884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 53
Colorectal cancer surveillance after index colonoscopy: guidance from the Canadian Association of Gastroenterology. 指数结肠镜检查后的结直肠癌监测:来自加拿大胃肠病学协会的指导。
IF 2.7 4区 医学 Q2 Medicine Pub Date : 2013-04-01 DOI: 10.1155/2013/232769
Desmond Leddin, Robert Enns, Robert Hilsden, Carlo A Fallone, Linda Rabeneck, Daniel C Sadowski, Harminder Singh

Background: Differences between American (United States [US]) and European guidelines for colonoscopy surveillance may create confusion for the practicing clinician. Under- or overutilization of surveillance colonoscopy can impact patient care.

Methods: The Canadian Association of Gastroenterology (CAG) convened a working group (CAG-WG) to review available guidelines and provide unified guidance to Canadian clinicians regarding appropriate follow-up for colorectal cancer (CRC) surveillance after index colonoscopy. A literature search was conducted for relevant data that postdated the published guidelines.

Results: The CAG-WG chose the 2012 US Multi-Society Task Force (MSTF) on Colorectal Cancer to serve as the basis for the Canadian position, primarily because the US approach was the simplest and comprehensively addressed the issue of serrated polyps. Aspects of other guidelines were incorporated where relevant. The CAG-WG recommendations differed from the US MSTF guidelines in three main areas: patients with negative index colonoscopy should be followed-up at 10 years using any of the appropriate screening tests, including colonoscopy, for average-risk individuals; among patients with >10 adenomas, a one-year interval for subsequent colonoscopy is recommended; and for long-term follow-up, patients with low-risk adenomas on both the index and first follow-up procedures can undergo second follow-up colonoscopy at an interval of five to 10 years.

Discussion: The CAG-WG adapted the US MSTF guidelines for colonoscopy surveillance to the Canadian health care environment with a few modifications. It is anticipated that the present article will provide unified guidance that will enhance physician acceptance and encourage appropriate utilization of recommended surveillance intervals.

背景:美国(United States [US])和欧洲结肠镜检查指南的差异可能会给临床医生带来困惑。监测结肠镜检查的不足或过度使用会影响患者的护理。方法:加拿大胃肠病学协会(CAG)召集工作组(CAG- wg)审查现有指南,并为加拿大临床医生提供关于指数结肠镜检查后结肠直肠癌(CRC)监测的适当随访的统一指导。对相关资料进行了文献检索,以寻找出版指南之后的相关数据。结果:CAG-WG选择2012年美国结直肠癌多社会工作组(MSTF)作为加拿大立场的基础,主要是因为美国入路是最简单和全面解决锯齿状息肉问题的方法。其他准则的各个方面在有关情况下被纳入。CAG-WG的建议与美国MSTF指南在三个主要方面有所不同:阴性结肠镜检查患者应在10年内使用任何适当的筛查试验(包括结肠镜检查)对平均风险个体进行随访;在>10个腺瘤的患者中,建议每隔一年进行结肠镜检查;对于长期随访,在指数和第一次随访程序中均为低风险腺瘤的患者可以每隔5至10年进行第二次随访结肠镜检查。讨论:CAG-WG对美国MSTF结肠镜监测指南进行了一些修改,以适应加拿大的卫生保健环境。预计本文将提供统一的指导,以提高医生的接受度,并鼓励适当使用推荐的监测间隔。
{"title":"Colorectal cancer surveillance after index colonoscopy: guidance from the Canadian Association of Gastroenterology.","authors":"Desmond Leddin,&nbsp;Robert Enns,&nbsp;Robert Hilsden,&nbsp;Carlo A Fallone,&nbsp;Linda Rabeneck,&nbsp;Daniel C Sadowski,&nbsp;Harminder Singh","doi":"10.1155/2013/232769","DOIUrl":"https://doi.org/10.1155/2013/232769","url":null,"abstract":"<p><strong>Background: </strong>Differences between American (United States [US]) and European guidelines for colonoscopy surveillance may create confusion for the practicing clinician. Under- or overutilization of surveillance colonoscopy can impact patient care.</p><p><strong>Methods: </strong>The Canadian Association of Gastroenterology (CAG) convened a working group (CAG-WG) to review available guidelines and provide unified guidance to Canadian clinicians regarding appropriate follow-up for colorectal cancer (CRC) surveillance after index colonoscopy. A literature search was conducted for relevant data that postdated the published guidelines.</p><p><strong>Results: </strong>The CAG-WG chose the 2012 US Multi-Society Task Force (MSTF) on Colorectal Cancer to serve as the basis for the Canadian position, primarily because the US approach was the simplest and comprehensively addressed the issue of serrated polyps. Aspects of other guidelines were incorporated where relevant. The CAG-WG recommendations differed from the US MSTF guidelines in three main areas: patients with negative index colonoscopy should be followed-up at 10 years using any of the appropriate screening tests, including colonoscopy, for average-risk individuals; among patients with >10 adenomas, a one-year interval for subsequent colonoscopy is recommended; and for long-term follow-up, patients with low-risk adenomas on both the index and first follow-up procedures can undergo second follow-up colonoscopy at an interval of five to 10 years.</p><p><strong>Discussion: </strong>The CAG-WG adapted the US MSTF guidelines for colonoscopy surveillance to the Canadian health care environment with a few modifications. It is anticipated that the present article will provide unified guidance that will enhance physician acceptance and encourage appropriate utilization of recommended surveillance intervals.</p>","PeriodicalId":55285,"journal":{"name":"Canadian Journal of Gastroenterology","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2013-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2013/232769","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31383887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 35
Multidisciplinary teams as standard of care in inflammatory bowel disease. 多学科团队作为炎症性肠病的标准治疗。
IF 2.7 4区 医学 Q2 Medicine Pub Date : 2013-04-01 DOI: 10.1155/2013/710671
Subrata Ghosh
Inflammatory bowel diseases (IBD), ulcerative colitis and Crohn disease have been associated with extraintestinal manifestations. These include arthralgia and arthritis, erythema nodosum, pyoderma gangrenosum, primary sclerosing cholangitis and autoimmune hepatitis, episcleritis and uveitis. Increasingly, other conditions, such as psoriasis and multiple sclerosis, have been described to be associated with IBD. It may be proper to consider IBD to be one of a spectrum of immune-mediated inflammatory diseases (IMIDs) clustered according to genetic predisposition and immunological imbalance. In general, IMIDs affect young people at the peak of their working life and, therefore, are associated with a high societal cost (1). Extraintestinal manifestations are important predictors of morbidity and temporary work disability (1). IBD is managed by gastroenterologists and, when required, by colorectal surgeons, but ideally should be managed in the setting of a multidisciplinary team. In the current issue of the Canadian Journal of Gastroenterology, this is illustrated by the report from Maastricht (The Netherlands) by Stolwijk et al (2) (pages 199–205) demonstrating the high prevalence of self-reported musculoskeletal spondyloarthropathy (SpA) in patients with IBD. However, one-half of these patients never consulted a rheumatologist. The population-based cumulative incidence of SpA in Crohn disease is reported to be 6.7% at 10 years, 13.9% at 20 years and 18.6% at 30 years. However, this may have missed patient-reported musculoskeletal symptoms. Lack of rheumatology referral misses an opportunity for accurate diagnosis, appropriate imaging and management strategies. SpA may follow a disease course separate from the activity of IBD and, therefore, may warrant therapeutic strategies dictated by musculoskeletal disease burden and morbidity. These include consideration of nonsteroidal anti-inflammatory drugs (NSAIDs) in the context of IBD, immunosuppressive drugs and anti-tumour necrosis factor (anti-TNF) agents. SpAs are also a group of overlapping, chronic inflammatory rheumatic diseases; therefore, accurate phenotyping is important for management. Musculoskeletal symptoms may also be a side effect of drug therapy in IBD such as delayed hypersensitivity reactions to anti-TNF agents, thiopurines, nutritional deficiencies and corticosteroid withdrawal. Equally important is to recognize that gastrointestinal symptoms in patients with SpA may be a manifestation of IBD and require investigation by a gastroenterologist. In general, the extraintestinal manifestations of IBD and the associated IMIDs respond to anti-TNF therapy, except primary sclerosing cholangitis. However, the use of etanercept may rarely be associated with development of IBD. Etanercept is ineffective in IBD and, therefore, SpA in the presence of IBD should be treated with the anti-TNF monoclonal antibodies. Other IMIDs, such as psoriasis and drug-induced lupus, may manifest while under tre
{"title":"Multidisciplinary teams as standard of care in inflammatory bowel disease.","authors":"Subrata Ghosh","doi":"10.1155/2013/710671","DOIUrl":"https://doi.org/10.1155/2013/710671","url":null,"abstract":"Inflammatory bowel diseases (IBD), ulcerative colitis and Crohn disease have been associated with extraintestinal manifestations. These include arthralgia and arthritis, erythema nodosum, pyoderma gangrenosum, primary sclerosing cholangitis and autoimmune hepatitis, episcleritis and uveitis. Increasingly, other conditions, such as psoriasis and multiple sclerosis, have been described to be associated with IBD. It may be proper to consider IBD to be one of a spectrum of immune-mediated inflammatory diseases (IMIDs) clustered according to genetic predisposition and immunological imbalance. In general, IMIDs affect young people at the peak of their working life and, therefore, are associated with a high societal cost (1). Extraintestinal manifestations are important predictors of morbidity and temporary work disability (1). \u0000 \u0000IBD is managed by gastroenterologists and, when required, by colorectal surgeons, but ideally should be managed in the setting of a multidisciplinary team. In the current issue of the Canadian Journal of Gastroenterology, this is illustrated by the report from Maastricht (The Netherlands) by Stolwijk et al (2) (pages 199–205) demonstrating the high prevalence of self-reported musculoskeletal spondyloarthropathy (SpA) in patients with IBD. However, one-half of these patients never consulted a rheumatologist. The population-based cumulative incidence of SpA in Crohn disease is reported to be 6.7% at 10 years, 13.9% at 20 years and 18.6% at 30 years. However, this may have missed patient-reported musculoskeletal symptoms. Lack of rheumatology referral misses an opportunity for accurate diagnosis, appropriate imaging and management strategies. SpA may follow a disease course separate from the activity of IBD and, therefore, may warrant therapeutic strategies dictated by musculoskeletal disease burden and morbidity. These include consideration of nonsteroidal anti-inflammatory drugs (NSAIDs) in the context of IBD, immunosuppressive drugs and anti-tumour necrosis factor (anti-TNF) agents. SpAs are also a group of overlapping, chronic inflammatory rheumatic diseases; therefore, accurate phenotyping is important for management. Musculoskeletal symptoms may also be a side effect of drug therapy in IBD such as delayed hypersensitivity reactions to anti-TNF agents, thiopurines, nutritional deficiencies and corticosteroid withdrawal. Equally important is to recognize that gastrointestinal symptoms in patients with SpA may be a manifestation of IBD and require investigation by a gastroenterologist. \u0000 \u0000In general, the extraintestinal manifestations of IBD and the associated IMIDs respond to anti-TNF therapy, except primary sclerosing cholangitis. However, the use of etanercept may rarely be associated with development of IBD. Etanercept is ineffective in IBD and, therefore, SpA in the presence of IBD should be treated with the anti-TNF monoclonal antibodies. Other IMIDs, such as psoriasis and drug-induced lupus, may manifest while under tre","PeriodicalId":55285,"journal":{"name":"Canadian Journal of Gastroenterology","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2013-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2013/710671","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31383882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 11
Prevalence of self-reported spondyloarthritis features in a cohort of patients with inflammatory bowel disease. 一组炎症性肠病患者自我报告的脊柱炎特征的患病率
IF 2.7 4区 医学 Q2 Medicine Pub Date : 2013-04-01 DOI: 10.1155/2013/139702
Carmen Stolwijk, Marieke Pierik, Robert Landewé, Ad Masclee, Astrid van Tubergen

Background: Musculoskeletal symptoms belonging to the spectrum of 'seronegative spondyloarthritis' (SpA) are the most common extraintestinal manifestations in patients with inflammatory bowel disease (IBD) and may lead to important disease burden. Patients with suspected SpA should be referred to a rheumatologist for further evaluation.

Objective: To investigate the self-reported prevalence of musculoskeletal SpA features in a cohort of patients with IBD and to compare this with actual referrals to a rheumatologist.

Methods: Consecutive patients with IBD visiting the outpatient clinic were interviewed by a trained research nurse about possible SpA features using a standardized questionnaire regarding the presence or history of inflammatory back pain, peripheral arthritis, enthesitis, dactylitis, psoriasis, uveitis and response to nonsteroidal anti-inflammatory drugs. All patient files were verified for previous visits to a rheumatologist and any rheumatic diagnosis.

Results: At least one musculoskeletal SpA feature was reported by 129 of 350 (36.9%) patients. No significant differences between patients with Crohn disease and ulcerative colitis were found. Review of medical records showed that 66 (51.2%) patients had ever visited a rheumatologist. Axial SpA was diagnosed in 18 (27.3%) patients, peripheral SpA in 20 (30.3%) patients and another rheumatic disorder in 14 (21.2%) patients.

Conclusion: Musculoskeletal SpA features are frequently present in patients with IBD. However, a substantial group of patients is not evaluated by a rheumatologist. Gastroenterologists play a key role in early referral of this often debilitating disease.

背景:属于“血清阴性脊柱炎”(SpA)谱系的肌肉骨骼症状是炎症性肠病(IBD)患者最常见的肠外表现,并可能导致重要的疾病负担。疑似SpA的患者应转诊给风湿病专家作进一步评估。目的:调查一组IBD患者自我报告的肌肉骨骼SpA特征的患病率,并将其与风湿病学家的实际转诊进行比较。方法:连续的IBD患者到门诊就诊时,由一名训练有素的研究护士对其进行访谈,询问可能的SpA特征,使用标准化的问卷调查,包括炎症性背痛、周围关节炎、鼻炎、指突炎、牛皮癣、葡萄膜炎的存在或病史,以及对非甾体抗炎药的反应。所有的病人档案都经过风湿病学家和任何风湿病诊断的验证。结果:350例患者中有129例(36.9%)报告了至少一种肌肉骨骼SpA特征。克罗恩病与溃疡性结肠炎患者间无显著差异。对医疗记录的回顾显示,66例(51.2%)患者曾就诊于风湿病专家。18例(27.3%)患者被诊断为轴向SpA, 20例(30.3%)患者被诊断为外周SpA, 14例(21.2%)患者被诊断为其他风湿病。结论:肌肉骨骼的SpA特征经常出现在IBD患者中。然而,有相当一部分患者没有接受风湿病专家的评估。胃肠病学家在这种经常使人衰弱的疾病的早期转诊中起着关键作用。
{"title":"Prevalence of self-reported spondyloarthritis features in a cohort of patients with inflammatory bowel disease.","authors":"Carmen Stolwijk,&nbsp;Marieke Pierik,&nbsp;Robert Landewé,&nbsp;Ad Masclee,&nbsp;Astrid van Tubergen","doi":"10.1155/2013/139702","DOIUrl":"https://doi.org/10.1155/2013/139702","url":null,"abstract":"<p><strong>Background: </strong>Musculoskeletal symptoms belonging to the spectrum of 'seronegative spondyloarthritis' (SpA) are the most common extraintestinal manifestations in patients with inflammatory bowel disease (IBD) and may lead to important disease burden. Patients with suspected SpA should be referred to a rheumatologist for further evaluation.</p><p><strong>Objective: </strong>To investigate the self-reported prevalence of musculoskeletal SpA features in a cohort of patients with IBD and to compare this with actual referrals to a rheumatologist.</p><p><strong>Methods: </strong>Consecutive patients with IBD visiting the outpatient clinic were interviewed by a trained research nurse about possible SpA features using a standardized questionnaire regarding the presence or history of inflammatory back pain, peripheral arthritis, enthesitis, dactylitis, psoriasis, uveitis and response to nonsteroidal anti-inflammatory drugs. All patient files were verified for previous visits to a rheumatologist and any rheumatic diagnosis.</p><p><strong>Results: </strong>At least one musculoskeletal SpA feature was reported by 129 of 350 (36.9%) patients. No significant differences between patients with Crohn disease and ulcerative colitis were found. Review of medical records showed that 66 (51.2%) patients had ever visited a rheumatologist. Axial SpA was diagnosed in 18 (27.3%) patients, peripheral SpA in 20 (30.3%) patients and another rheumatic disorder in 14 (21.2%) patients.</p><p><strong>Conclusion: </strong>Musculoskeletal SpA features are frequently present in patients with IBD. However, a substantial group of patients is not evaluated by a rheumatologist. Gastroenterologists play a key role in early referral of this often debilitating disease.</p>","PeriodicalId":55285,"journal":{"name":"Canadian Journal of Gastroenterology","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2013-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2013/139702","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31383883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 52
Immunization history of children with inflammatory bowel disease. 儿童炎症性肠病的免疫接种史。
IF 2.7 4区 医学 Q2 Medicine Pub Date : 2013-04-01 DOI: 10.1155/2013/539524
Ing Shian Soon, Jennifer C C deBruyn, Iwona Wrobel

Background: Protection against vaccine-preventable diseases is important in children with inflammatory bowel disease (IBD) due to frequent immunosuppressive therapy use. The chronic relapsing nature and treatment regimen of IBD may necessitate modified timing of immunizations.

Objective: To evaluate the completeness of immunizations in children with IBD.

Methods: Immunization records of all children with IBD followed at the Alberta Children's Hospital (Calgary, Alberta) were reviewed. For children with incomplete immunization according to the province of Alberta schedule, the reasons for such were clarified. Demographic data and age at diagnosis were also collected.

Results: Immunization records were obtained from 145 (79%) children with IBD. Fifteen children had incomplete routine childhood immunizations, including two with no previous immunizations. The most common incomplete immunizations included hepatitis B (n=9), diphtheria, tetanus, acellular pertussis at 14 to 16 years of age (n=7), and diphtheria, tetanus, acellular pertussis, inactivated polio at four to six years of age (n=6). The reasons for incomplete immunization included use of immunosuppressive therapy at time of scheduled immunization; IBD-related symptoms at time of scheduled immunization; parental refusal; recent move from elsewhere with different immunization schedule; unawareness of routine immunization; and needle phobia.

Conclusions: Although the majority of children with IBD had complete childhood immunizations, suboptimal immunizations were present in 10%. With increasing use of immunosuppressive therapy in IBD, physicians caring for children with IBD must periodically evaluate immunization status and ensure the completeness of childhood immunizations.

背景:由于频繁使用免疫抑制治疗,预防疫苗可预防疾病对炎症性肠病(IBD)儿童很重要。IBD的慢性复发性质和治疗方案可能需要修改免疫接种时间。目的:评价儿童IBD免疫接种的完全性。方法:回顾在Alberta儿童医院(Calgary, Alberta)随访的所有IBD患儿的免疫记录。对于未按照艾伯塔省时间表进行免疫接种的儿童,澄清了其原因。还收集了人口统计数据和诊断年龄。结果:145例(79%)IBD患儿获得免疫接种记录。15名儿童的常规儿童免疫接种不完全,其中2名以前没有接种过免疫。最常见的不完全免疫包括乙型肝炎(n=9)、白喉、破伤风、14至16岁的无细胞百日咳(n=7),以及4至6岁的白喉、破伤风、无细胞百日咳、灭活脊髓灰质炎(n=6)。免疫不完全的原因包括在计划免疫时使用免疫抑制治疗;在计划免疫接种时出现ibd相关症状;父母的拒绝;最近从免疫计划不同的其他地方采取的行动;不了解常规免疫接种;还有针头恐惧症。结论:尽管大多数IBD患儿有完整的儿童免疫接种,但有10%的儿童免疫接种不理想。随着免疫抑制治疗在IBD中的应用越来越多,照顾IBD儿童的医生必须定期评估免疫状况,并确保儿童免疫接种的完整性。
{"title":"Immunization history of children with inflammatory bowel disease.","authors":"Ing Shian Soon,&nbsp;Jennifer C C deBruyn,&nbsp;Iwona Wrobel","doi":"10.1155/2013/539524","DOIUrl":"https://doi.org/10.1155/2013/539524","url":null,"abstract":"<p><strong>Background: </strong>Protection against vaccine-preventable diseases is important in children with inflammatory bowel disease (IBD) due to frequent immunosuppressive therapy use. The chronic relapsing nature and treatment regimen of IBD may necessitate modified timing of immunizations.</p><p><strong>Objective: </strong>To evaluate the completeness of immunizations in children with IBD.</p><p><strong>Methods: </strong>Immunization records of all children with IBD followed at the Alberta Children's Hospital (Calgary, Alberta) were reviewed. For children with incomplete immunization according to the province of Alberta schedule, the reasons for such were clarified. Demographic data and age at diagnosis were also collected.</p><p><strong>Results: </strong>Immunization records were obtained from 145 (79%) children with IBD. Fifteen children had incomplete routine childhood immunizations, including two with no previous immunizations. The most common incomplete immunizations included hepatitis B (n=9), diphtheria, tetanus, acellular pertussis at 14 to 16 years of age (n=7), and diphtheria, tetanus, acellular pertussis, inactivated polio at four to six years of age (n=6). The reasons for incomplete immunization included use of immunosuppressive therapy at time of scheduled immunization; IBD-related symptoms at time of scheduled immunization; parental refusal; recent move from elsewhere with different immunization schedule; unawareness of routine immunization; and needle phobia.</p><p><strong>Conclusions: </strong>Although the majority of children with IBD had complete childhood immunizations, suboptimal immunizations were present in 10%. With increasing use of immunosuppressive therapy in IBD, physicians caring for children with IBD must periodically evaluate immunization status and ensure the completeness of childhood immunizations.</p>","PeriodicalId":55285,"journal":{"name":"Canadian Journal of Gastroenterology","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2013-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2013/539524","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31383885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 19
Treatment of chronic hepatitis C infection among current and former injection drug users within a multidisciplinary treatment model at a community health centre. 在社区卫生中心采用多学科治疗模式治疗目前和以前注射吸毒者中的慢性丙型肝炎感染。
IF 2.7 4区 医学 Q2 Medicine Pub Date : 2013-04-01 DOI: 10.1155/2013/515636
Adam Isaiah Newman, Shelley Beckstead, David Beking, Susan Finch, Tina Knorr, Carol Lynch, Meredith MacKenzie, Daphne Mayer, Brenda Melles, Ron Shore

The aim of the present prospective observational study was to assess uptake and success of hepatitis C virus (HCV) treatment among a group of former and current injection drug users with chronic HCV infection at the Street Health Centre in Kingston, Ontario. The Street Health Centre offers hepatitis C education, assessment and treatment within a multidisciplinary, integrated and collaborative treatment model of care delivered by primary care professionals. The study enrolled a convenience sample of 34 patients. Seventy per cent of study patients had no postsecondary education, 85% were unemployed and one-third were unstably housed. A majority of study patients self-reported mental health problems. Of the 14 patients who initiated antiviral treatment in the study period, eight (57%) achieved sustained virological response. Regardless of virological outcome, patients who initiated treatment showed positive trends toward increased social and psychiatric stability, and decreases in high-risk behaviours. These results suggest that not only is successful treatment of chronic HCV infection in current and former injection drug users with concurrent psychiatric disorders possible, but the benefits of such treatment delivered in a community-based, multidisciplinary, primary care model may extend beyond narrowly defined virological outcomes.

本前瞻性观察性研究的目的是评估安大略省金斯敦街道卫生中心一组既往和现期注射吸毒者对丙型肝炎病毒(HCV)治疗的吸收和成功率。街道卫生中心在初级保健专业人员提供的多学科、综合和协作治疗模式下提供丙型肝炎教育、评估和治疗。这项研究纳入了34名患者的方便样本。70%的研究患者没有受过高等教育,85%失业,三分之一的患者住房不稳定。大多数研究患者自我报告有心理健康问题。在研究期间开始抗病毒治疗的14名患者中,有8名(57%)获得了持续的病毒学应答。无论病毒学结果如何,开始治疗的患者都表现出积极的趋势,即社会和精神稳定性增强,高危行为减少。这些结果表明,目前和以前的注射吸毒者并发精神疾病,不仅有可能成功治疗慢性丙型肝炎病毒感染,而且在社区、多学科、初级保健模式中提供这种治疗的好处可能超出狭义的病毒学结果。
{"title":"Treatment of chronic hepatitis C infection among current and former injection drug users within a multidisciplinary treatment model at a community health centre.","authors":"Adam Isaiah Newman,&nbsp;Shelley Beckstead,&nbsp;David Beking,&nbsp;Susan Finch,&nbsp;Tina Knorr,&nbsp;Carol Lynch,&nbsp;Meredith MacKenzie,&nbsp;Daphne Mayer,&nbsp;Brenda Melles,&nbsp;Ron Shore","doi":"10.1155/2013/515636","DOIUrl":"10.1155/2013/515636","url":null,"abstract":"<p><p>The aim of the present prospective observational study was to assess uptake and success of hepatitis C virus (HCV) treatment among a group of former and current injection drug users with chronic HCV infection at the Street Health Centre in Kingston, Ontario. The Street Health Centre offers hepatitis C education, assessment and treatment within a multidisciplinary, integrated and collaborative treatment model of care delivered by primary care professionals. The study enrolled a convenience sample of 34 patients. Seventy per cent of study patients had no postsecondary education, 85% were unemployed and one-third were unstably housed. A majority of study patients self-reported mental health problems. Of the 14 patients who initiated antiviral treatment in the study period, eight (57%) achieved sustained virological response. Regardless of virological outcome, patients who initiated treatment showed positive trends toward increased social and psychiatric stability, and decreases in high-risk behaviours. These results suggest that not only is successful treatment of chronic HCV infection in current and former injection drug users with concurrent psychiatric disorders possible, but the benefits of such treatment delivered in a community-based, multidisciplinary, primary care model may extend beyond narrowly defined virological outcomes.</p>","PeriodicalId":55285,"journal":{"name":"Canadian Journal of Gastroenterology","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2013-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2013/515636","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31383886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 38
期刊
Canadian Journal of Gastroenterology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1